GSK drug helps ovarian cancer patients live longer

GSK drug helps ovarian cancer patients live longer

GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening says a late-stage study. The study, called PRIMA, tested the treatment as maintenance therapy in women who have undergone platinum-based chemotherapy and met the main goal for women regardless of their biomarker status, GSK said. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co’s Lynparza and Clovis Oncology’s Rubraca.

Reuters

Related Stories

No stories found.
Aster Medical Journal
www.theamj.org